Reply To: Scrips 2012

Herbalist Forums Scripts Scrips 2012 Reply To: Scrips 2012

#340
Avatarwebmaster
Keymaster

Calcium may enhance probiotic survival in the gut, cut cholesterol levels

Combining calcium phosphate supplements with probiotic Lactobacillus paracasei may enhance the colonization of the probiotic in the gut, and boost reductions in LDL cholesterol levels, says a new study with humans. — Calcium in the form of pentacalcium hydroxy-triphosphate, combined with Lactobacillus paracasei (LPC37) was associated with significant reductions in total and LD cholesterol following four weeks of supplementation, and the results were greater than those observed for L. paracasei alone, according to findings published in Clinical Nutrition. –“To the best of our knowledge, there are no published studies examining the influence of a combinatory supplement consisting of probiotics and calcium phosphate on the faecal microbiota and on cholesterol metabolism in humans,” wrote researchers from Friedrich Schiller University Jena in Germany. –“The results of the present human study imply that calcium phosphate positively affects the colonization of LPC37 in the human gut under conditions of combinatory supplementation of calcium phosphateand LPC37.

“This combined supplementation is also capable of beneficially modulating blood lipids in healthy, hypercholesterolemic men and women.” –Probiotic potential – The study adds to the ever growing body of science supporting the potential benefits of probiotics. — On Tuesday, an elegant study by Dr Jeff Gordon and his team at the Washington University School of Medicine in St. Louis revealed that probiotic bacteria consumed in a yogurt may not change the host’s gut populations, but they do influence carbohydrate metabolism by the resident microbes. — The new study suggests that calcium phosphate may enhance the activities of L. paracasei. –Study details — Led by Gerhard Jahreis, the Jena, Germany-based researchers recruited 34 omnivorous men and women with moderately elevated blood cholesterol levels to participate in their double-blind, placebo-controlled, cross-over study. — Participants were divided into two groups: One was provided with a probiotic drink containing 10 billion colony forming units (CFUs) per day of L. paracasei (Danisco) for four weeks, while the second group received the probiotic plus an additional gram of pentacalcium hydroxy-triphosphate. — After the intervention period, all participants had a two week period without intervention – the so-called wash out period – followed by two weeks of receiving placebo. After this they were crossed over to the other intervention for another four weeks. — Results showed that the combined intervention was associated with a significant reduction in total and LDL cholesterol levels, compared with the probiotic alone and placebo. —“There are two possible explanations for this observation,” said the researchers, “either LPC37 and calcium phosphate act synergistically, or the cholesterol-lowering effect of LPC37 + calcium phosphate is due to the action of calcium phosphate in the human gut.” — With reference to other studies that have shown an effect of calcium supplementations on blood lipids to a similar extent as measured in the current study, the researchers proposed that the “cholesterol-lowering effect is solely due to the calcium phosphate supplement”. — In addition, the level of L. paracasei and all lactobacilli in the feces increase significantly following both the combined and probiotic only interventions, compared with placebo.

“There was a significantly positive correlation between the fecal concentration of calcium and the concentration of L. paracasei,” wrote the researchers.

“This supports the hypothesis that calcium phosphate positively influences the colonization of L. paracasei in the human gut.” Source: Clinical Nutrition Published online ahead of print, doi: 10.1016/j.clnu.2011.09.013 “A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans” Authors: U. Trautvetter, B. Ditscheid, M. Kiehntopf, G. Jahreis

********************************************************************************************************

Probiotics may influence carbohydrate metabolism

Probiotic bacteria consumed in a yogurt may not change the host’s gut populations, but they do influence carbohydrate metabolism by the resident microbes, according to an ‘elegant’ new study using identical twins and germ-free mice. — Probiotics in a yogurt were not found to colonize the gut microflora when studied in identical twins, but additional study in mice revealed that ingestion of the probiotic bacteria produced a change in many metabolic pathways, particularly those related to carbohydrate metabolism. — Researchers led by Dr Jeffrey Gordon at the Washington University School of Medicine, St. Louis, published their results yesterday in Science Translational Medicine. — In an accompanying perspective article the study was described as “elegant” by Jordan Bisanz and Gregor Reid from the Lawson Health Research Institute at the University of Western Ontario.

Dr Gordon and his team have made a habit of advancing our understanding of gut microbe populations and their interactions with their hosts. In 2006, the St Louis-based researchers reported in Nature (Vol. 444, pp. 1022-1023, 1027-1031) that microbial populations in the gut are different between obese and lean people, and that when the obese people lost weight their microflora reverted back to that observed in a lean person, suggesting that obesity may have a microbial component. –Roadmap

“One of the questions that this field is asking is what are the effects of these organisms on individuals,” said Dr Gordon in an audio podcast with Science Translational Medicine . —“Can we create a discovery pipeline where we can analyze their effects under highly controlled conditions – more controlled than we can achieve with human studies – and having interrogated those models, can we translate the information to humans to guide clinical trials, and gain a greater degree of insight about their effects?” — And that is what the researchers appear to have created. According to Bisanz and Reid, “a valuable roadmap has now been produced to guide future research on how exogenous organisms affect the host – and specifically its microbiome”. — In an email to NutraIngredients-USA, Prof Reid added: “The study is important as it tests a probiotic food in humans then investigates the mechanisms of action using a variety of state-of-the-art methods. The researchers then create a reduced microbiota in an animal and show that the effects of the probiotic can to some extent be mimicked.” —Study details — Dr Gordon and his team examined the potential of four months of consuming a commercial yogurt containing Bifidobacterium animalis subsp. lactis, two strains of Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilis, and Lactococcus lactis subsp. cremoris, in seven pairs of female twins in their 20s and 30s. Dr Gordon has not named the product to avoid being seen as endorsing it. — The researchers also tested the effects of the yogurt in gnotobiotic mice, or mice that were completely germ-free except for the 15 specially introduced strains of bacteria that are present in the human gut. — Results showed that, in both mice and humans, the probiotic yogurt did not modify the composition of the gut microbial communities. — However, further analysis of using genome sequencing, and transcriptomic and metabolomic analyses, revealed a change in marked changes in numerous metabolic pathways, particularly those related to the processing of carbohydrates. — According to Bisanz and Reid, “a real strength of [Dr Gordon’s] study is that ingestion of a fermented milk product, essentially a commercial probiotic yogurt, was monitored by having the microbial transcriptional responses from the animal model acting as biomarkers for interrogation of the metatranscriptome data sets of the human twins. —“The apparent stability of the twins’ gut microbiota, despite a twice daily intake of the fermented milk product containing bifidobacteria and lactic acid-producing bacteria, demonstrates the remarkable ability of the host’s microbes to withstand the arrival of new strains of bacteria.”

What next? — Dr Gordon and his co-workers note that his team’s experimental model could be used to identify biomarkers and other ‘mediators of the effects of existing or new probiotic strains’ The model may also help scientists identify potential new prebiotics that could also modify the metabolic effects of probiotic species. — Bisanz and Reid added that the “incredible precision and thoroughness of [Dr Gordon’s] study will not be easy to duplicate, but they have certainly laid a valuable pathway for others to follow.” Source: Science Translational Medicine 26 October 2011, Volume 3, Issue 106, 106ra106 “The Impact of a Consortium of Fermented Milk Strains on the Gut Microbiome of Gnotobiotic Mice and Monozygotic Twins” Authors: N.P. McNulty, T. Yatsunenko; A. Hsiao, et al.

***********************************************************************************************

Pineapple bromelain has anti-tumor properties superior to the chemo-agent 5-fluorouracil. – In vivo antitumoral activity of stem pineapple (Ananas comosus) bromelain.

Abstract Source: Planta Med. 2007 Oct;73(13):1377-83. Epub 2007 Sep 24. PMID: 17893836

Abstract Author(s): Roxana Báez, Miriam T Lopes, Carlos E Salas, Martha Hernández

Abstract—–Stem bromelain (EC 3.4.22.32) is a major cysteine proteinase,[U1] isolated from pineapple ( Ananas comosus) stem. Its main medicinal use is recognized as digestive, in vaccine formulation, antitumoral and skin debrider for the treatment of burns. To verify the identity of the principle in stem fractions responsible for the antitumoral effect, we isolated bromelain to probe its pharmacological effects. The isolated bromelain was obtained from stems of adult pineapple plants by buffered aqueous extraction [U2]and cationic chromatography. The homogeneity of bromelain was confirmed by reverse phase HPLC, SDS-PAGE and N-terminal sequencing. The in vivo antitumoral/antileukemic activity was evaluated using the following panel of tumor lines: P-388 leukemia, sarcoma (S-37), Ehrlich ascitic tumor (EAT), Lewis lung carcinoma (LLC), MB-F10 melanoma and ADC-755 mammary adenocarcinoma. Intraperitoneal administration [U3]of bromelain (1, 12.5, 25 mg/kg), began 24 h after tumor cell inoculation in experiments in which 5-fluorouracil (5-FU, 20 mg/kg) was used as positive control. The antitumoral activity was assessed by the survival increase (% survival index) following various treatments. With the exception of MB-F10 melanoma, all other tumor-bearing animals had a significantly increased survival index after bromelain treatment. The largest increase ( approximately 318 %) was attained in mice bearing EAT ascites and receiving 12.5 mg/kg of bromelain. This antitumoral effect was superior to that of 5-FU, whose survival index was approximately 263 %, relative to the untreated control. Bromelain significantly reduced the number of lung metastasis induced by LLC transplantation, as observed with 5-FU. The antitumoral activity of bromelain against S-37 and EAT, which are tumor models sensitive to immune system mediators, and the unchanged tumor progression in the metastatic model suggests that the antimetastatic action results from a mechanism independent of the primary antitumoral effect.

Pubmed Data : Planta Med. 2007 Oct;73(13):1377-83. Epub 2007 Sep 24. PMID: 17893836 Article Published Date : Oct 01, 2007

Study Type : Animal Study

Diseases : Cancer Metastasis : CK(230) : AC(120), Lung Cancer : CK(423) : AC(182)

Pharmacological Actions : Anti-metastatic : CK(152) : AC(95)

Additional Keywords : Drug: 5-flourouracil : CK(68) : AC(23), Food as Medicine : CK(15) : AC(6), Hall of Fame : CK(26) : AC(6), Superiority of Natural Substances versus Drugs : CK(776) : AC(172)

*************************************************************************

Plant Extraction

The plant materials were cleaned of residual soil and air-dried at room temperature. Plants were ground to a fine powder using a laboratory mill and passed through a 24 mesh sieve to generate a homogeneous powder, stored at room temperature (22–23 °C), and protected from light until extraction.

Methanolic extractions were conducted using 250 mg sample of each ground plant material, of the used parts (see Table (1), in 10 mL methanol (80%), at 37 °C for 3 h, in a shaking water bath. After cooling, the extract was centrifuged at 1500 g for 10 min, and the supernatant was recovered. The solvent was evaporated under vacuum at 40°C using a rotary evaporator. The solid residues were collected and stored in dry condition until analysis

( this is away to concentrate your remedy by allowing the materials to be in a solvent sealed and placed in 100degree water so that the materials will extract and become even more concentrated and then poured into a evaporator to remove all the alcohol and residue to all you have is a extract )

Preparation of Extract for In Vitro Assay

The tested extracts were initially dissolved in DMSO to give five different stock solutions with a concentration range of 0.625-10.0 mg/mL (0.625, 1.25, 2.5, 5.0 and 10mg/mL). Subsequently, 20 μL aliquot of each stock solution was used in the reaction mixture to give a final concentration range of 12.5- 200 μg/mL (12.5, 25, 25, 50 and 200 μg/mL).

**************************************************************************

Serrapeptase’s Uses

Serrapeptase is known in several other names such as serralysin, serratiapeptase, serratia peptidase, serratio peptidase, or serrapeptidase and is derived from the microorganism called Serratiopeptidase which is found present in the intestines of silkworm which allows the emerging moth to dissolve its cocoon. Serrapeptase is produced by purification from culture of Serratia E-15 bacteria.

It is an enzyme that eats or digests non-living tissue, blood clots, cysts, arterial plaque, inflammation, internal scar tissue as well as help with new external scars by either converting it into amino acids or excreted in the normal manner. Here are a few uses for Serrapeptase:

As a natural solution to pain & inflammation–With Serrapeptase, chronic inflammation can be resolved or minimized in a natural and balanced way. Symptoms of inflammation disappear within 1 to 2 weeks but health practitioners normally recommend administration for up to 4 weeks to reassess the condition. –As a natural alternative to NSAIDs–Since the discovery of Serrapeptase and its wonderful healing properties with inflammation, it has become the favored choice compared to salicylates, ibuprofen and the more potent NSAIDs. Because Serrapeptase is naturally occurring, there fore no inhibitory effects on prostaglandins have been recorded and is devoid of gastrointestinal side effects.

As an alternative to Warfarin—Warfarin is known for its blood thining properties that is why the proper dosage each time is sued and monitored. Serrapeptase also has blood thinning properties though not as potent as Warfarin. Many natural remedies and dietary improvements will thin the blood naturally that is why a doctor’s recommendation is always needed. Though that, blood thinning at certain levels is good as it makes the blood healthy if the blood is already too thick and the platelets are sticking together. Serrapeptase does not thin blood in an unhealthy way, rather it promotes healthy production of blood cells to stop chronic inflammation.

As treatment for arterial blockage—Dr. Hans Neiper’s findings for serrepeptase is probably the main reason why serrapeptase is popular. Dr. Hans found that Serrapeptase has properties of treating arterial blockage in his coronary patients. It works by dissolving blood clots and shrinking varicose veins. Several of Dr. Hans’ patients who were scheduled for amputation recovered quickly through treatments of Serrapeptase. Serrapeptase is always known as a natural anti-inflammatory and as a strong protease that can dissolves the dead proteins that bind the plaque blocking the arteries. —As a natural inflammation treatment for: Arthritis, Ankylosing Spondylitis, Osteoporosis, Lupus, Diabetes, MS, Headaches and Migraines caused by inflammation –Lungs – Emphysema, Bronchitis, Pulmonary Tuberculosis, Bronchial Asthma, Cystic Fibrosis, Bronchiectasis etc ,Inflammatory bowel diseases such as Crohn’s, Colitis etc, Inflammation in joints or muscles e.g. Fibromyalgia, Repetitive strain injuries, Breast Engorgement, Fibrocystic Breast Disease, Cysts, Cardiovascular Disease, Arterial Disease, Angina, Blood clots, Varicose Veins, Eye, nose and throat problems from inflammation or blocked veins – ear infections, hayfever, swollen glands, laryngitis, rhinitis, sinusitis, runny nose,Sports Injuries, traumatic swelling, post operative swellings, leg ulcers Post operative healing -Enlarged Prostate

************************************************************************

Serrapeptase Effects and Heals – can safely remove inflammation and dead tissue that causes pain, blocked arteries, varicose veins, lung problems and other common symptoms.–Serrapeptase, serrazyme, Serraplus+, serraplus+, inflammation, blocked arteries, varicose veins, dead tissue, lung problems, scar tissue, scars, Pain, Ankylosing Spondylitis, Arthritis, back problems, Diabetes, Leg Ulcers, Osteoporosis, Polymyalgia Rheumatica, Prostate Problems, Repetitive Strain (RSI) Carpal Tunnel, Rheumatoid Arthritis, Breast Engorgement, Cystitis, joints or muscles, Fibromyaligia, Fibrocystic Breast Disease, Headaches, Migranes, Inflammatory bowel diseases, Ulcerative Colitis, Crohn’s, IBS, Lupus, Lung, Chest, Asbestosis, Miners and Farmers Lung, Bronchietasis, Bronchial Asthma, Bronchitis, Coughs, Cystic Fibrosis, Emphysema, Pulmonary Tuberculosis, Eye Problems, Blocked veins, Multiple Sclerosis, MS, Neurological problems, Damaged Nerves, Ear, Nose, Throat problems, Chronic ear infections, Catarrhal Rhinopharyngitis, Hayfever, Sore Throat, Swollen Glands, Laryngitis, Runny nose, Rhinitis, Sinusitis problems, Trauma, Sports Injuries prevention.

********************************************************************

Serrapeptase Reference

l.. Kee WH. Tan SL, Lee V. Salmon YM. The treatment of breast engorgement with Serrapeptase (Danzen): a random ized double-blind controlled trial. Singapore Med J. 1989:30(1):48-54.

2. M izukoshi, D. et al. A double-blind clinical study of serrapeptase in the treatment of chronic sinusitis. Igaku Ayrni 109:50-62.1979.

3. Carratu, L. et al. Physio-chemical and rheological research on mucolytic activity of serrapeptase in chronic broncho-pneumopathies. Curr. Ther. Res. 28(6):937-951. 1980.

4. Braga, P.C. et al. Effects of serrapeptase on muco-ciliary clearance in patients with chronic bronchitis. Curr. Ther. Res. 29(5):738-744,1981.

5. Mazzonie, A. et al. Evaluation of serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind randomized trial versus placebo. J. int. Med. Res. 18(5):379-388,1990.

6. Kakinumu, A. et al. Regression of fibrinolysis in scalded rats by administration of serrapeptase. Biochem. Pharmacol. 31:2861-2866,1982.

7. Marly, M. Enzymotherapie anti-inflammatoire a l’aide de la serrapeptase: resultats cliniques en traumatologie et en ORL. C RTherapeut. 3:9-19,1985.

8. Odagiri, J. et al. Clinical applications of serrapeptase in sinusitis. Med. Consult. New Remedy 6:201-209, 1979.

9. Yamazaki, J. et al. Anti-inflammatory activity of TSP, a protease produced by a strain of Serratia. Folia Pharmacol. Japon. 6^302-314,1967.

I0. Harad~, Y. Clinical efficacy of serrapeptase on buccal swelling after radical operation for chronic sinusitis. Igaku Ayumi 123:768-778.1982.

1 I. Matsudo, A. et at. Effect of serrapeptase (Danzen) on inflammatory edema following operation for thyroid disease. Med. Consult. New Remedy 18:171-175, 1981.

12. Fujitani, T. et al. Effect of anti-inflammatory agent on transfer of antibiotics to the maxillary sinus mucosa in chronic sinusitis. Otorhinolaryngol. Clin. North Am. 66:557-565. 1976.

13. Tago. T. and Mitsui, S. Effects of serrapeptase in dissolution of sputum, especially in patients with bronchial asthma. Jap. Clin. Exp. Med. 49:222-228, 1972.

14. Mazzonie, A. et al. Evaluation of serrapeptase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind randomized trial versus placebo. J. int. Med. Res. 18(5):379-388,1990.

15. Kase, Y. et al. A new method for evaluating mucolytic expectorant activity and its application. II. Application to two proteolytic enzymes, serrapeptase and seaprose. Arzneimittelforschung 32:374-378,1982.

16. Marriott, C. Modification of the rheoloaical properties of mucus by drugs. Adv. Exp. Med. Biol. 144^75-84, 1982.

17. Majima. Y. et al. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am. Rev. Respit. Dis. 141:79-83.1990.

18. Miyata, K. Intestinal absorption of serrapeptase. J ApplBiochem. 1980:2:111-16.

19. Aso T. et al. Breast engorgement and its treatment: Clinical effects of Danzen (serrapeptase) an anti-inflammatory enzyme preparation. The world of Obstetrics and Gynecology (Japanese). 1981:33:371-9.

20. Esch PM, Gemgross H. Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase-a prospective study (German). FortschrMed. 1989; 107(4):67-8, 71-2.

21. Majima Y, lnagaki M, Hirata K. Takeuchi K, M orishita A, Sakakura Y. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol. 1988;244(6):355-9.

22. Selan L, Berlutti F, Passariello C. Comodi-Ballanti MR, Thaller MC. ?roteolytic enzymes: a new treatment strategy for prosthetic infections? Antimicrob Agents Cheroother. 1993; 37(12):2618-21.

23. Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu H, Hirata M, Arai T, et al. Augmentation by serrapeptase of tissue permeation by cefotiam (Japanese). Jpn JAntibiot. 1986; 39(3):761-7

*******************************************************************************************

TOP A

[U1]Cysteine Protein or amino
[U2]The boiled them down

[U3]The membrane that lines the walls of the abdomen and the pelvis (called the parietal peritoneum) and encloses the abdominal and pelvic organs (called the visceral peritoneum.)
*****************************************************************************************************************
TOP B

HOME

 

Show Of The Week January 6 2012

Artificial sweetener consumption is associated with urinary tract tumors.– Aceslfame K

Effect of a Herbal-Leucine mix on the IL-1β-induced cartilage degradation and inflammatory gene expression in human chondrocytes.

Anti-tumorigenic activity of five culinary and medicinal herbs grown under greenhouse conditions and their combination effects

DHA used in infant formula products comes from genetically modified algae

Antioxidant capacity of hesperidin from citrus peel using electron spin resonance and cytotoxic activity against human carcinoma cell lines.

*************************************************************************

Artificial sweetener consumption is associated with urinary tract tumors. – Aceslfame K

Artificial sweetener consumption and urinary tract tumors in Cordoba, Argentina.

Prev Med. 2008 Jul;47(1):136-9. Epub 2008 Apr 8. PMID: 18495230

Abstract Author(s): M M Andreatta, S E Muñoz, M J Lantieri, A R Eynard, A Navarro Article Affiliation:

Escuela de Nutrición, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Argentina. Abstract:

OBJECTIVE: To determine the role of the habitual use of the most common artificial sweeteners (AS) in the development of urinary tract tumors (UTT) in Argentina. METHODS: Case-control study of 197 patients with histologically confirmed UTT of transitional varieties, and 397 controls with acute, non-neoplastic, and non-urinary tract diseases, admitted to the same hospitals in Córdoba (Argentina) between 1999 and 2006. All subjects were interviewed about their use of AS and their exposure to other known or suspected risk factors for UTT. RESULTS: Fifty-one UTT patients (26%) and 87 controls (22%) used AS. The risk of UTT was significantly increased in long-term (>or =10 years) AS users compared with none-AS users. The OR (95% CI) for long-term consumers was 2.18 (1.22-3.89) and for short-term users was 1.10 (0.61-2.00) after adjustment for age, gender, BMI, social status. and years of tobacco use. CONCLUSION: Regular use of AS for 10 years or more was positively associated with UTT.–Study Type : Human Study

***************************************************************************

Effect of a Herbal-Leucine mix on the IL-1β-induced cartilage degradation and inflammatory gene expression in human chondrocytes.

BMC Complement Altern Med. 2011;11:66-Authors: Akhtar N, Miller MJ, Haqqi TM

Abstract
BACKGROUND: Conventional treatments for the articular diseases are often effective for symptom relief, but can also cause significant side effects and do not slow the progression of the disease. Several natural substances have been shown to be effective at relieving the symptoms of osteoarthritis (OA), and preliminary evidence suggests that some of these compounds may exert a favorable influence on the course of the disease. The objective of this study was to investigate the anti-inflammatory/chondroprotective potential of a Herbal and amino acid mixture containing extract of the Uncaria tomentosa, ( cats claw) Boswellia spp ( myrrh or frankinsense )., Lepidium meyenii( maca ) and L-Leucine on the IL-1β-induced production of nitric oxide (NO), glycosaminoglycan (GAG), matrix metalloproteinases (MMPs), aggrecan (ACAN) and type II collagen (COL2A1) in human OA chondrocytes and OA cartilage explants.—METHODS: Primary OA chondrocytes or OA cartilage explants were pretreated with Herbal-Leucine mixture (HLM, 1-10 μg/ml) and then stimulated with IL-1β (5 ng/ml). Effect of HLM on IL-1β-induced gene expression of iNOS, MMP-9, MMP-13, ACAN and COL2A1 was verified by real time-PCR. Estimation of NO and GAG release in culture supernatant was done using commercially available kits. –RESULTS: HLM tested in these in vitro studies was found to be an effective anti-inflammatory agent, as evidenced by strong inhibition of iNOS, MMP-9 and MMP-13 expression and NO production in IL-1β-stimulated OA chondrocytes (p < 0.05). Supporting these gene expression results, IL-1β-induced cartilage matrix breakdown, as evidenced by GAG release from cartilage explants, was also significantly blocked (p < 0.05). Moreover, in the presence of herbal-Leucine mixture (HLM) up-regulation of ACAN and COL2A1 expression in IL-1β-stimulated OA chondrocytes was also noted (p < 0.05). The inhibitory effects of HLM were mediated by inhibiting the activation of nuclear factor (NF)-kB in human OA chondrocytes in presence of IL-1β.
CONCLUSION: Our data suggests that HLM could be chondroprotective and anti-inflammatory agent in arthritis, switching chondrocyte gene expression from catabolic direction towards anabolic and regenerative, and consequently this approach may be potentially useful as a new adjunct therapeutic/preventive agent for OA or injury recovery.—PMID: 21854562 [PubMed – indexed for MEDLINE]–You can do this several ways—anytime you increase nitric oxide reduce inflammation ( sodium phosphate) cayenne and tumeric and pineapple –you may see this sort of thing reverse—especially when adding gelatin and comfrey to your daily regimen—or utilizing anti catabolic ( stops the break down of muscle and tissue) substances or materials or foods.

************************************************************************

Anti-tumorigenic activity of five culinary and medicinal herbs grown under greenhouse conditions and their combination effects.

J Sci Food Agric. 2011 Aug 15;91(10):1849-54

Authors: Yi W, Wetzstein HY

Abstract
BACKGROUND: Herbs and spices have been used as food preservatives, flavorings, and in traditional medicines for thousands of years. More and more scientific evidence supports the medicinal properties of culinary herbs. Colon cancer is the third leading cause of cancer death in the USA, and the fourth most common form of cancer worldwide. The objectives of this study were to evaluate the antitumor activity of five selected herbs grown under greenhouse conditions, and to study the potential synergistic effects among different herbal extract combinations.
RESULTS: Thyme, rosemary, sage, spearmint, and peppermint extracts significantly inhibited SW-480 colon cancer cell growth, with sage extracts exhibiting the highest bioactivity, with 50% inhibition at 35.9 µg mL⁻¹, which was equivalent to 93.9 µg dried leaves mL⁻¹ of culture medium. Some mixtures of different herbal extracts had combination effects on cancer cell growth. The inhibitory effects of peppermint + sage combinations at a 1:1 ratio were significantly higher than rosemary + sage combinations at 1:1 ratio, although peppermint extracts showed lower inhibition than rosemary extracts.–CONCLUSION: Extracts from herb species (thyme, rosemary, sage, spearmint and peppermint) can significantly inhibit the growth of human colon cancer cells. Mixtures of herb extracts can have combination effects on cancer cell growth. The study suggests that these five herbs may have potential health benefits to suppress colon cancer.PMID: 21452174 [PubMed – indexed for MEDLINE]

***********************************************************************

DHA used in infant formula products comes from genetically modified algae

One of the most vulnerable segments of the population — infants — are being affected as chemical giant Martek Biosciences uses cronyism to have its patented GMO products classified as organic. The National Organic Program is trying to correct this, but in the meantime the “organic” infant formula or baby food parents feed their children could contain industrial Frankenfood.

History of Irresponsibility—-The story of how this state of affairs came about reveals much on how politics and profit can undermine food safety. Here’s a timeline on how the word “organic” is being undermined, creating a health threat for babies who are fed with formula.

2002: Food manufacturers begin supplementing infant formula and baby food with synthetic forms of docosahexaenoic acid (DHA) and arachidonic acid (ARA). These polyunsaturated omega-3 and omega-6 fatty acids, naturally present in breast milk, are important components of the human brain and eyes. Although the form of DHA/ARA used in infant formulas is structurally incompatible with the form found in human milk, food manufacturers market their products with the claim that their formulas will make babies more intelligent.

2006: In spite of the fact that its synthetic DHA/ARA is from laboratory-grown fermented algae and fungus through the use of hexane, a petroleum by-product and EPA-identified neurotoxin, Martek applies for organic status for its products. The USDA’s National Organic Program (NOP) tells Martek its synthetic DHA and ARA does not quality as organic. Martek attorney J. Friedman ignores the decision of NOP staff and contacts NOP director Barbara Robinson to have the decision reversed.

2009: A front page Washington Post article, “Integrity of Federal ‘Organic’ Label Questioned” uncovers the Martek story. The article quotes Martek’s lawyer saying “I called Robinson up, I wrote an e-mail. It was a simple matter.”

2002-2010: Parents and medical professionals observe reactions in babies fed with products containing Life’s DHA, the product name Martek gives its patented GMO version of naturally occurring fatty acids. The range of infant health problems includes difficulties breathing and gastrointestinal disorders. When affected babies are no longer fed the formula, the ailments disappear. Although Freedom of Information Act requests reveal hundreds of FDA adverse event reports, the FDA is slow to react.

2011: FDA announces it will investigate claims that DHA/ARA infant formulas support brain and eye development. The National Organic Program is now trying to remedy its 2006 decision by asking Martek to formally ask permission of the NOP’s National Organic Standards Board to use its DHA and AHA in organic products.

Products Containing this GMO

In the meantime, Life’s DHA is being sold in many so-called organic brands which many consumers trust. Paying higher prices for products labeled as organic does not necessarily mean your family’s food does not include this particular Frankenfood. From Martek’s own website, here is a list of infant formulas containing their product which is both genetically modified and typically manufactured using a known toxin:

Earth’s Best Organic Soy with DHA & ARA (Hain Celestial Group)

Enfamil LIPIL (Mead Johnson Nutritionals)

Enfamil Next Step (Mead Johnson)

Isomil 2 Advance (Abbott Laboratories)

Nestle Good Start Supreme with DHA & ARA (Nestle USA)

Parent’s Choice Organic (Wal-Mart)

Similac Advance (Abbott Nutrition)

Ultra Bright Beginnings Lipids (PBM Products, LLC)

There is also a long list of pre-natal supplements as well as vitamins and dietary supplements for infants, children and adults containing this product. A surprisingly wide range of foods and beverages use this GMO substance including Apple Bran Muffins sold at Starbucks; Farm Pride Omega-3 Eggs; Horizon Organic Milk; Kroger Active Lifestyle Premium Light OJ Beverage; Minute Maid Enhanced Pomegranate Blueberry Juice; Pediasure Children’s Beverage; Pompeian OlivExtra Plus and Silk Soymilk. The list of products containing this GMO is multinational, with products in many countries across the globe. If you want to check whether a supplement, food, or beverage you use contains Life’s DHA, the full list is here: http://www.lifesdha.com/Products-Co&#8230;

**************************************************************************

Antioxidant capacity of hesperidin from citrus peel using electron spin resonance and cytotoxic activity against human carcinoma cell lines.

Pharm Biol. 2011 Mar;49(3):276-82—Authors: Al-Ashaal HA, El-Sheltawy ST

Abstract

CONTEXT: Hesperidin is a flavonoid that has various pharmacological activities including anti-inflammatory, antimicrobial and antiviral activities.

OBJECTIVE: The aim of the study is the isolation of hesperidin from the peel of Citrus sinensis L. (Rutaceae), and the evaluation of its antioxidant capacity and cytotoxicity against different human carcinoma cell lines.

MATERIALS AND METHODS: In the present work, hesperidin is identified and confirmed using chromatographic and spectral analysis. To correlate between hesperidin concentration and antioxidant capacity of peel extracts, extraction was carried out using 1% HCl-MeOH, MeOH, alkaline solution, the concentration of hesperidin determined qualitatively and quantitatively using high performance thin layer chromatography (HPTLC), high performance liquid chromatography (HPLC) analysis, in vitro antioxidant capacity of hesperidin and the extracts against free radical diphenylpicrylhydrazyl (DPPH•) performed using an electron spin resonance spectrophotometer (ESR). Cytotoxic assay against larynx, cervix, breast and liver carcinoma cell lines was performed.- RESULTS: Hesperidin was found to be moderately active as an antioxidant agent; its capacity reached 36%. In addition, the results revealed that hesperidin exhibited pronounced anticancer activity against the selected cell lines. IC₅₀ were 1.67, 3.33, 4.17, 4.58 µg/mL, respectively.– DISCUSSION AND CONCLUSION: Orange peels are considered to be a cheap source for hesperidin which may be used in the pharmaceutical industry as a natural chemopreventive agent. Hesperidin and orange peel extract could possess antioxidant properties with a wide range of therapeutic applications.–PMID: 21323480 [PubMed – indexed for MEDLINE]

TOP B

**************************************************************************************************

TOP C

HOME

 

Show Of The Week January 9 2012

 

Delay Breastfeeding to “Improve” Vaccination?

Senators Give Supplements a Lifeline

When Overeating, Calories — Not Protein — Contribute to Increase in Body Fat
Fountain of Youth in Bile- Longevity Molecule Identified

Cancer-Killing Compound Spares Healthy Cells- Lithocholic acid

*************************************************************************

Delay Breastfeeding to “Improve” Vaccination?

Over the course of the past few years, we have been gathering studies from the US National Library of Medicine on the adverse, unintended health effects of vaccination [1], in an attempt to offset the one-sided propaganda foisted upon the public, namely, that all vaccines are unequivocally “safe” and “effective,” a priori. —Along the way, we happened upon a 2010 study [2] published in the Journal of Pediatric Infections & Diseases which has been shared more than any other article on our database, and which suggests that breastfeeding should be delayed in order to prevent immune factors within breast milk from inactivating vaccine-associated antibody titer elevations and “vaccine potency.” The concluded the study with the following statement:–“INTERPRETATION: The lower immunogenicity and efficacy of rotavirus vaccines in poor developing countries could be explained, in part, by higher titers of IgA and neutralizing activity in breast milk consumed by their infants at the time of immunization that could effectively reduce the potency of the vaccine. Strategies to overcome this negative effect, such as delaying breast-feeding at the time of immunization, should be evaluated.”—It is not difficult to comprehend what caused the flurry of interest in this study. Readers were a the obviously disturbed by the suggestion that women in the underdeveloped world temporarily stop breast feeding (often the only source of infant nutrition) in order to increase the vaccine’s purported “efficacy.” Are we to assume that these breast milk deprived infants should consume formula* in the interim? And to what end? So that the vaccine can generate a temporary spike in antibody production, which is no measure of real-world effectiveness? —*Note: Infant formula has been linked to 48 adverse effects [3], including increased mortality.—First, it should be made clear that the term “efficacy,” when used in the context of a vaccine’s antibody-elevating effects, does not equate to effectiveness, i.e. whether or not a vaccine actually works in real life to protect against the infectious agent of concern.–It is this semantic trick (conflating and confusing “efficacy” with “effectiveness”) which convinces most of the “developed” world that vaccine research is “evidence-based” and focused on creating enhanced immunity, when in fact it is primarily a highly successful business enterprise dependent on defrauding its “customers” of both their money and health. The dangers of common vaccines [1] are so well known by “health experts,” and the manufacturers who produce, them that their risk (like nuclear power) is underwritten by world governments. The importance of this fact can not be overestimated or understated.———–Introducing foreign pathogenic DNA, chemicals, metals, preservatives, etc., into the body through a syringe will generate a response not unlike kicking a bee hive. The harder you kick that beehive, the greater will be the “efficacy” (i.e. elevated antibodies), but the actual affinity that these antibodies will have for the antigen (i.e. pathogen) of concern, can not be guaranteed; nor must the vaccine reseachers prove antibody-antigen affinity to receive FDA approval. –Also, valuable immune resources are wasted by generating “false flag” responses to threats which may not readily exist in the environment, e.g. there are over 200 forms of influenza A, B & C which can cause the symptoms associated with annual influenza A, so the seasonal trivalent flu vaccine only takes care of little more than 1% of the possible vectors of infection – and often at the price of distracting resources away from real threats and exhausting and/or damaging the entire immune apparatus. Truth be told, there is actually a shocking lack of evidence to support flu vaccines [4], in any age or population.—What’s worse, the vaccine response can “blow back” causing loss of self-tolerance and, via the resultant Th2 dominant immune system, the body can attack itself (auto-immunity). In the meantime, the first line of defense against infection (Th1) is compromised and this “front door” can be left wide open to unmet infectious challenges.—It is clear that one can create a synthetic immune response through vaccination, but it is not likely to result in enhanced immunity, insofar as real-world effectiveness is concerned, which is the only true judge of whether a vaccine is valuable or not. One might view the basic criteria used by vaccine researchers, namely, that generating elevated antibody titers proves the value of the vaccine, oppositely: proving the vaccine is causing harm to the developing infant by generating unnecessarily elevated antibodies by any means necessary, i.e. throwing the chemical and biological kitchen sink at the immune system, e.g. aluminum, phenol, diploid (aborted fetal) cells, peanut oil, pertactin, etc. –In the same way that secretory IgA from breast milk [5] deactivates a broad range of “natural” antigenic challenges for the infant, this breast milk derived, indispensable immune factor also deactivates the inherently disruptive and immunotoxic antibody-generating vaccine antigens and adjuvants. Rather than view this as the “enemy,” the reduction in antibodies that accompanies a well-nourished breastfed infant’s blood work, after the highly invasive and unnatural introduction of a vaccine, is a sign of health, not disease.—-This study struck a deep psychic chord out there. Images of phallic syringes stabbing away jealously at the symbolic breast of Nature come to mind, as the increasingly invasive ethos of modern medicine — always attempting to “improve on Nature” — drives us sick, mentally and physically. Can’t we just leave the timeless wisdom of mothering and nourishing that is woven into the mother-infant dyad alone?

Additional Topics:

Infant Formula: Risk Factor for 48 Diseases [3]

Breast Feeding: Risk Reduction for 59 Diseases [6]

Vaccination Research Database [1]

Article: Infant Formula For Disaster [7]

Vaccine researchers have suggested delaying breastfeeding to “improve” vaccine efficacy. Images of phallic syringes stabbing away jealously at the symbolic breast of Nature come to mind, as the increasingly invasive ethos of modern medicine — always attempting to “improve on Nature” — drives us sick, mentally and physically. Can’t we just leave the timeless wisdom of mothering and nourishing that is woven into the mother-infant dyad alone?

Source URL: http://www.greenmedinfo.com/blog/researchers-delay-breastfeeding-improve-vaccination

Links:
[1] http://www.greenmedinfo.com/page/vaccine-research
[2] http://www.greenmedinfo.com/article/vaccination-proponents-have-suggested-breastfeeding-should-be-delayed-order-prevent-immune-f
[3] http://www.greenmedinfo.com/toxic-ingredient/infant-formula
[4] http://www.greenmedinfo.com/blog/shocking-lack-evidence-supporting-flu-vaccines
[5] http://www.greenmedinfo.com/substance/breast-milk
[6] http://www.greenmedinfo.com/therapeutic-action/breastfeeding
[7] http://www.sayerji.com/published-writings/infant-formula-for-disaster

***************************************************************************

Senators Give Supplements a Lifeline

Will it be enough to rein in FDA’s outrageous power grab?

ANH-USA, together with a number of supplement trade organizations, went to Capitol Hill to plead our case about the FDA’s profoundly flawed NDI (new supplement) draft guidance in the offices of two powerful senators and longtime friends of natural health, Sen. Tom Harkin (D-IA) and Sen. Orrin Hatch (R-UT). Our visit was preceded by all the letters you have been sending to Congress, which have immeasurably increased the visibility of this issue. As you know, if this draft guidance stands, it would allow FDA to arbitrarily deny the sale of any supplement created (or modified) in the past seventeen years [1]. Immediately after this meeting, Sens. Harkin and Hatch wrote to FDA Commissioner Margaret Hamburg and formally asked the FDA to withdraw its guidance document.——-The senators urged FDA to begin work on a new draft that provides needed clarification on what constitutes a New Dietary Ingredient (NDI)—but, in their words, does not undermine Congress’s desire to provide consumers with access to safe, affordable dietary supplement products. Exactly!——–These senators were uniquely qualified to make such a request, since they were the principal authors of DSHEA, the Dietary Supplement Health and Education Act of 1994. “When Congress included language in the Food Safety Modernization Act (FSMA) directing FDA to clarify when a dietary supplement ingredient is a new dietary ingredient, the expectation was that the guidance would be consistent with DSHEA,” they write. “Unfortunately, the draft guidance serves to undermine DSHEA in a number of important respects.”

They go on to outline the various arguments that we have been making in these pages for some time:

The requirement for a manufacturer to submit an NDI notification for every dietary supplement containing an NDI is directly contrary to the language of DSHEA, which requires notification only of the intent to use an NDI;
This new requirement is burdensome and would impose substantial additional costs on manufacturers, would not provide additional safety benefits, and would undermine access to the safe, affordable nutritional supplements that DSHEA was designed to ensure;
The NDI guidance’s assertion that synthetic copies of ingredients can never be a dietary ingredient is without any statutory basis, and is contrary to longstanding FDA policy; and
This guidance is contrary to Congressional intent by grandfathering in only ingredients that were marketed before the enactment of DSHEA—such an argument is particularly specious since “the term dietary supplement wasn’t even defined prior to DSHEA”!
The senators requested that FDA meet with interested parties to work through all of the issues raised in our and others’ comments. Fortunately, FDA can’t just ignore the senators’ request, because the agency is required to work within legislative intent. Otherwise they would be creating new law—which legally they cannot do. This is one of the arguments we have been making all along—that FDA is in fact making new law with this draft guidance, and now Congress is calling them on it!—-We would like to thank Senators Harkin and Hatch for being such stalwart champions of natural health, and for their leadership in this battle to prevent the FDA from usurping powers that they are not legally entitled to. We also want to thank every one of you for contacting Congress and the FDA and being such a vital part of this process.—We aren’t out of the woods yet—we’ll have another update soon with additional action items for you. The time may come for more specific legislative action, and we may find ourselves battling FDA in the courts as well. That’s why your continued support and activism is so terribly important. Together we can win this one, preserve your access to supplements, and keep supplements from costing as much as drugs.